#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	15894	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2038	772.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1419	1419	C	878	C,T	835,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	15894	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2038	772.4	0	HET	.	.	.	C451T	.	451	451	C	686	686	C	887	C,T	429,414	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29018	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3782	765.9	0	.	n	.	0	T695C	SNP	695	695	T	1132	1132	C	858	C	807	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29018	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3782	765.9	0	.	n	.	0	A1638G	SNP	1638	1638	A	2075	2075	G	929	G,A	841,34	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29018	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3782	765.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2408	2408	C	922	C	884	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29018	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3782	765.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2482	2482	A	907	A	871	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29018	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3782	765.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3034	3034	C	913	C,A	863,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	1980	folP	855	855	100.0	folP.l6.c17.ctg.1	1516	129.6	1	SNP	p	R229S	1	.	.	685	687	AGC	1063	1065	AGC	197;195;196	A;G;C	189;187;186	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6636	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3354	197.2	1	SNP	p	S91F	1	.	.	271	273	TTC	558	560	TTC	223;223;225	T;T;C	216;215;214	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6636	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3354	197.2	1	SNP	p	G95N	0	.	.	283	285	GGC	570	572	GGC	218;220;221	G;G;C	208;209;207	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6636	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3354	197.2	1	SNP	p	D95G	1	.	.	283	285	GGC	570	572	GGC	218;220;221	G;G;C	208;209;207	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	1812	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1292	139.4	1	SNP	p	G45D	0	.	.	133	135	GGC	433	435	GGC	216;217;218	G;G;C	209;210;211	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	856	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	987	86.0	0	.	n	.	0	A197.	DEL	197	197	A	525	525	A	194	A	184	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6218	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3029	204.6	1	SNP	p	D86N	0	.	.	256	258	GAC	718	720	GAC	269;271;273	G;A;C	253;255;260	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6218	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3029	204.6	1	SNP	p	R87W	0	.	.	259	261	CGT	721	723	CGT	272;271;271	C,A;G;T	255,7;260;254	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6218	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3029	204.6	1	SNP	p	R87I	0	.	.	259	261	CGT	721	723	CGT	272;271;271	C,A;G;T	255,7;260;254	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6218	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3029	204.6	1	SNP	p	S87R	1	.	.	259	261	CGT	721	723	CGT	272;271;271	C,A;G;T	255,7;260;254	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6218	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3029	204.6	1	SNP	p	S88P	0	.	.	262	264	TCC	724	726	TCC	269;271;268	T;C;C	253;261;257	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4250	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2675	158.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1578	1580	GGC	230;229;228	G;G;C	218;215;215	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.35.001	penA.35.001	1	1	27	4026	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2421	164.3	1	SNP	p	A311V	0	.	.	931	933	GCC	1364	1366	GCC	225;227;231	G;C;C,A	209;210;211,4	penA.35.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	4026	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2421	164.3	1	SNP	p	I312M	1	.	.	934	936	ATG	1367	1369	ATG	230;232;234	A;T;G,C	214;213;212,4	penA.35.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	4026	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2421	164.3	1	SNP	p	T316P	0	.	.	946	948	ACC	1379	1381	ACC	235;231;233	A,G;C,T;C,G	213,1;212,1;216,1	penA.35.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	4026	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2421	164.3	1	SNP	p	V316T	1	.	.	946	948	ACC	1379	1381	ACC	235;231;233	A,G;C,T;C,G	213,1;212,1;216,1	penA.35.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	4026	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2421	164.3	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1880	1882	ACC	185;186;182	A;C;C,T	171;175;171,1	penA.35.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	4026	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2421	164.3	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1934	1936	GCG	196;196;197	G,A;C;G	166,5;163;164	penA.35.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	4026	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2421	164.3	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1934	1936	GCG	196;196;197	G,A;C;G	166,5;163;164	penA.35.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	4026	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2421	164.3	1	SNP	p	G542S	0	.	.	1624	1626	GGT	2057	2059	GGT	171;168;169	G;G;T,C	159;151;145,8	penA.35.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	4026	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2421	164.3	1	SNP	p	G545S	0	.	.	1633	1635	GGC	2066	2068	GGC	163;162;162	G;G;C	146;150;149	penA.35.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	4026	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2421	164.3	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2084	2086	CCG	157;158;156	C,G;C,T,A,G;G	122,5;119,7,1,1;118	penA.35.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5920	ponA	2397	2397	100.0	ponA.l15.c30.ctg.1	3229	182.9	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1689	1691	CCG	225;227;225	C;C;G	205;213;206	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2512	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1753	142.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	512	512	C	210	C	197	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	316	porB1a	984	331	90.15	porB1a.l6.c17.ctg.2	534	24.8	0	.	p	.	0	H217N	NONSYN	649	651	CAT	223	225	AAT	28;28;29	A;A;T	28;28;29	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	316	porB1a	984	331	90.15	porB1a.l6.c17.ctg.2	534	24.8	0	.	p	.	0	D218N	NONSYN	652	654	GAT	226	228	AAT	29;28;27	A;A;T	29;28;27	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	316	porB1a	984	331	90.15	porB1a.l6.c17.ctg.2	534	24.8	0	.	p	.	0	V226A	NONSYN	676	678	GTA	250	252	GCA	25;25;25	G;C;A	25;25;25	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	316	porB1a	984	331	90.15	porB1a.l6.c17.ctg.2	534	24.8	0	.	p	.	0	.	MULTIPLE	700	702	ACT	273	275	GTA	23;23;23	G;T;A	23;23;23	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	316	porB1a	984	331	90.15	porB1a.l6.c17.ctg.2	534	24.8	0	.	p	.	0	N237fs	FSHIFT	709	709	A	282	282	A	22	A	22	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3096	porB1b	1038	1038	99.81	porB1b.l15.c17.ctg.1	1367	221.6	0	.	p	.	0	I45V	NONSYN	133	135	ATT	341	343	GTT	259;258;257	G,A;T,G;T	244,7;239,7;245	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3096	porB1b	1038	1038	99.81	porB1b.l15.c17.ctg.1	1367	221.6	0	.	p	.	0	G48E	NONSYN	142	144	GGA	350	352	GAA	263;258;259	G;A,G;A	251;243,1;247	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3096	porB1b	1038	1038	99.81	porB1b.l15.c17.ctg.1	1367	221.6	1	SNP	p	G120K	1	.	.	358	360	AAG	566	568	AAG	262;265;264	A;A;G	249;255;251	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3096	porB1b	1038	1038	99.81	porB1b.l15.c17.ctg.1	1367	221.6	1	SNP	p	N121D	0	.	.	361	363	AAC	569	571	AAC	267;267;268	A,G;A;C	248,3;255;258	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3096	porB1b	1038	1038	99.81	porB1b.l15.c17.ctg.1	1367	221.6	1	SNP	p	A121N	1	.	.	361	363	AAC	569	571	AAC	267;267;268	A,G;A;C	248,3;255;258	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11568	rpoB	4179	4179	99.98	rpoB.l6.c30.ctg.1	5002	230.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1326	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1069	123.4	1	SNP	p	V57M	1	.	.	169	171	ATG	504	506	ATG	286;284;286	A;T;G	274;273;275	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
